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Abstract. – OBJECTIVE: Oncological treat-
ments are associated with toxicities that may de-
crease compliance to treatment in most genitouri-
nary cancer patients. Supplementation with phar-
maceutical-standardized supplement may be a 
supplementary method to control the side effects 
after chemo- and radiotherapy and the increased 
oxidative stress associated to treatments. This 
registry study evaluated a natural combination 
of supplements containing curcumin, cordyceps, 
and astaxanthin (Oncotris™) used as supplemen-
tary management in genitourinary cancer patients 
who had undergone oncological therapy. 
PATIENTS AND METHODS: Patients with 
genitourinary cancers (prostate or bladder ma-
lignancies) who had undergone and completed 
cancer treatments (radiotherapy, chemotherapy 
or intravesical immunotherapy with increased 
oxidative stress and residual symptoms) were 
recruited in this registry, supplement study. 
Registry subjects (n = 61) freely decided to 
follow either a standard management (SM) (con-
trol group = 35) or SM plus oral daily supple-
mentation (supplement group = 26). Evaluation 
of severity of treatment-related residual side 
effects, blood count test, prostate-specific anti-
gen (PSA) test and plasma free radicals (oxida-
tive stress) were performed at inclusion and at 
the end of the observational period (6 weeks).
RESULTS: Two patients dropped out during the 
registry. Therefore, the analysis included 59 partic-
ipants: 26 individuals in the supplementation group 
and 33 in the control group. In the supplement 
group, the intensity of signs and symptoms (treat-
ment-related) and residual side effects significant-
ly decreased at 6 weeks: minimal changes were 
observed in controls. Supplementation with On-
cotris™ was associated with a significant improve-
ment in blood cell count and with a decreased level 
of plasmatic PSA and oxidative stress. 
CONCLUSIONS: Naturally-derived supple-
ments, specifically Oncotris™ (patent pending), 
could support the body to overcome the treat-
ment-related toxicities – and the relative oxida-
tive stress in cancer patients.
Key Words
Genitourinary cancer, Prostate cancer, Bladder 
cancer, Treatment-related toxicities, Curcumin, Astax-
anthin, Cordyceps.
Introduction
Cancer is the second leading cause of death 
worldwide, following cardiovascular diseases; it 
was globally responsible for 8.8 million deaths 
in 20151. Between 2005 and 2015 cancer cases 
increased by 33%1. However, the cancer incidence 
is expected to increase further in the next decade 
due to population ageing. In the last years, signif-
icant advances have been achieved in early detec-
tion, diagnosis and treatment of cancer, leading to 
a prolonged survival rate an increasing number of 
cancer survivors2. Nowadays, some types of can-
cer may be managed as a chronic illness3. In this 
light, the goals for management of cancer patients 
should also include the improvement of their 
quality of life (QoL), by choosing personalized 
therapies and taking into account physical and 
psychological effects of long-term treatments4. 
In addition to symptoms related to the disease, 
treatment-related toxicities also affect patients’ 
QoL and physical and psychological functioning. 
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The majority of cancer patients experience one 
or more side effects correlated with therapy, 
with pain, depression and fatigue being the most 
frequently reported5. In particular, in genitouri-
nary cancers, such as prostate and bladder ma-
lignancies, patients who have been treated with 
surgery and radiation therapy commonly experi-
ence painful urination, hematuria, incontinence, 
infections, erectile dysfunction, and bowel com-
plications6. Chemotherapeutic agents induce al-
teration of blood parameters leading to increased 
risk of infections, easy bruising or bleeding and 
fatigue7. Usually, a combination of radiation and 
chemotherapy can also be used to treat invasive 
disease. In this complex scenario supplements 
with pharmaceutical standards (PS) may be both 
useful and safe, when prescribed on an individual 
basis, to control treatment-related side effects. 
Around one-third of prostate cancer patients use 
supplementary management to improve symp-
toms and alleviate treatment-related toxicities8,9 
very often associated to an increase in oxida-
tive stress. The pharmacological properties of 
PS supplements (including an anti-oxidant and 
anti-inflammatory activity) make their use justi-
fiable as supplementary management – planned 
on an individual basis – particularly in cancer 
patients, as PS supplements do not interfere with 
other treatments. Previous studies showed that 
curcumin alleviates most side effects of cancer 
chemo- and radiotherapy possibly through the 
curcumin ability to upregulate anti-oxidative 
responses and downregulate inflammatory path-
ways10-12. More studies are showing the effects 
of PS supplements and particularly curcumin in 
improving residual symptoms after cancer treat-
ment. This registry study evaluates a natural-
ly-derived, formulation (containing curcumin, 
cordyceps and astaxanthin) used as a supple-
ment in genitourinary cancer patients who had 
undergone oncological treatments.
Patients and Methods
This was a registry, supplement study conduct-
ed in patients with genitourinary cancers (pros-
tate or bladder malignancies) who had undergone 
and completed cancer treatments (radiotherapy, 
chemotherapy or intravesical immunotherapy), at 
least one week before inclusion. 
The following patients were eligible:
  • Adult subjects affected by prostate (T1/T2) or 
bladder cancer;
  • Subjects who completed cancer treatments 
(radiotherapy, chemotherapy or intravesical 
immunotherapy), at least 1 week before in-
clusion.
The following patients were excluded:
  • Subjects who had thrombosis or infections;
  • Subjects who are being treated or taking 
medications due to other chronic or major 
diseases;
  • Subjects who are allergic to food related to the 
investigational product or pharmaceuticals.
Supplement studies define the field of activ-
ity of pharma-standard supplements and their 
possible preventive, pre-therapeutic applications. 
“Supplement human studies” produce supple-
mentary data to be compared with those from the 
best available management plans. These types of 
studies are performed with products with high 
level of safety and pharmaceutical standards and 
as non-interventional trials involving a food sup-
plement, they do not strictly require the Ethics 
Committee approval13-15. Informed participants 
(n=61) freely decided to follow either a validated 
standard management (SM) to control the treat-
ment-related side effects (control group = 35) 
or SM plus oral daily supplementation (supple-
ment group = 26). Daily supplementation dos-
age consisted of 2 tablets of a multi-component 
formulation (Oncotris™: Idroflu s.r.l., Conegliano, 
TV, Italy), for 6 weeks. The multi-component 
product includes: a delivery form of curcumin 
Enterosoma® [a delivery form of curcuma con-
taining Curcuma Longa L. extract standardized 
to 95% curcuminoids, N-acetylcysteine, grape-
fruit (Citrus paradisi Macfad) seeds, chitosan 
derived from shellfish, resveratrol derived from 
Polygonum cuspidatum Sieb. et Zucc rizoma, 
black pepper (Piper nigrum L.) fruit, emulsifier 
(polysorbate 80)]; astaxantin (derived from Hae-
matococcus pluvialis); cordyceps (Cordyceps sin-
ensis). Clinical assessments and laboratory exams 
were performed at inclusion and at the end of the 
observational period (6 weeks) and included:
  • Evaluation of severity of treatment-related 
side effects by using an arbitrary analogue 
scale ranging from 0 (absence of side effects) 
to 5 (very severe side effects requiring medi-
cal attention);
  • Blood count test;
  • Prostate-Specific Antigen (PSA) test;
  • Plasma free radical test: oxidative stress was 
evaluated by diacron-reactive oxygen metab-
olites (d-ROMs) test, through free radical an-
alytical system (FRAS).
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Statistical Analysis
Intragroup comparisons were performed by 
using Student t-test. p-value <0.05 was consid-
ered statistically significant.
Results
Overall 61 patients with genitourinary can-
cers who were previously treated with standard 
therapy were recruited in this study. As two 
participants dropped out during the study period, 
the final analysis set included 59 participants: 
26 individuals in the supplementation group 
and 33 in the control group. The age of patients 
ranged from 58 to 74 years. The distributions 
of type of cancer and related treatment in the 
study group are shown in Table I. Table II 
summarizes the treatment-related side effects 
severity assessed by an arbitrary analogue scale. 
In supplemented patients, the intensity of signs 
and symptoms evaluated significantly decreased 
after the observational period. On the other side, 
no significant changes were observed in the 
control group. In addition, supplementation with 
Oncotris™ was associated with a significant im-
provement in hematological parameters, partic-
ularly in hemoglobin level (13.9±1.0 vs. 13.8±1.1 
g/dL), number of red blood cells (4.8±0.6 vs. 
4.6±0.7, expressed as 106/mm3) and white blood 
cells (4.8±0.5 vs. 4.3±0.8 expressed as 106/mm3) 
(Table III). A significant increase in number of 
red blood cells was also recorded in patients 
who received standard management only. Blood 
exam also revealed a decreased level of PSA and 
free radicals in supplemented patients at the end 
Table I. Genitourinary cancer and treatment distribution in 
the study group.
Genitourinary  Standard  Standard
  cancer and management management +
  treatments  Oncotris™
Prostate cancer
   Chemotherapy 8 6
   Radiotherapy 7 4 
Bladder cancer
   Chemotherapy 8 6
   Radiotherapy 5 5 
   Intravesical 6 5 
     immunotherapy
TOTAL 33 26
Table II. Evaluation of the severity of treatment-related side effects in patients with genitourinary cancers.
Range of arbitrary analogue scale: 0 (no side effects) – 5 (severe side effects requiring medical attention). Data are expressed as 
mean±standard deviation. *p<0.05 vs. inclusion.
 Standard Management Standard Management + Oncotris™
 Inclusion 6 weeks Inclusion 6 weeks
Symptoms
   Pain 4.3±0.7 3.3±1.1 4.6±0.2 3.1±1.0*
   Dysuria  3.2±1.2 3.0±1.1 3.8±1.1 2.1±0.7*
   Urgency 3.4±0.4 3.1±0.6 3.7±1.2 2.0±1.0*
   Infections 3.4±0.3 2.5±0.7 3.3±0.5 1.2±0.3*
   Nausea/vomiting 2.3±0.5 2.0±0.2 2.2±0.4 1.0±0.5*
   Fatigue 3.4±0.8 3.0±0.9 3.5±1.0 2.1±0.7*
Signs
   Hematuria 3.0±0.3 2.4±0.6 3.1±0.4 2.0±0.5*
   Retention 3.7±0.8 2.8±0.7 3.6±1.0 1.8±0.4*
Table III. Blood count test in in patients pre-treated for genitourinary cancers. Data are expressed as mean±standard deviation. 
*p<0.05 vs. inclusion.
 Standard Management Standard Management + Oncotris™
 Inclusion 6 weeks Inclusion 6 weeks
Hemoglobin (g/dL) 13.8±1.0 13.8±1.1 13.8±1.1 13.9±1.0*
Red blood cells (106/mm3) 4.4±0.4 4.5±0.7* 4.6±0.7 4.8±0.6*
White blood cells (103/mm3) 4.3±1.0 4.3±0.5 4.3±0.8 4.8±0.5*
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of the study period (5.3±1.1 ng/mL and 344±28 
U-CARR, respectively), compared with baseline 
values (6.9±1.5 ng/mL and 427±33 U-CARR, 
respectively) (Figures 1 and 2). 
Safety
All subjects correctly took the supplementa-
tion showing a complete adherence to treatment 
(100%) and complete compliance (100%) to the 
proposed protocol. No adverse effects, neither 
toxicities, were reported.
Discussion
Treatment-related toxicities decrease tolerance 
and compliance in all (including) genitourinary 
cancer patients. A prompt diagnosis and adequate 
management of these treatment-related toxicities 
could help to prevent or alleviate fatigue, nausea, 
vomiting, malaise, diarrhea, rashes, infections, 
headaches, and other problems and improve the 
patients’ quality of life. One of the most promis-
ing approaches to effectively manage side effects 
in cancer therapies (especially chemo- and radio-
Figure 1. The level of plas-
matic prostate specific anti-
gen (PSA) in our study pop-
ulation. *p <0.05. 
Figure 2. Plasmatic free rad-
ical level in our study popula-
tion. *p <0.05.
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therapy) is non-pharmacologic intervention based 
on dietary supplementation16,17. In our registry, a 
remarkable improvement in the side-effect profile 
was observed in genitourinary cancer patients 
(prostate or bladder tumors) supplemented with 
a naturally-based multi-component formulation 
(Oncotris™). This clinical benefit could be as-
cribed to the biological properties of each sup-
plementation components. Curcumin is an active 
compound isolated from Curcuma longa which 
has gained considerable interest over the last 
decades due to its beneficial effects for human 
health18. Its well-known and documented anti-ox-
idant and anti-inflammatory actions10,19 could ex-
plain the reduction of pain, infections, dysuria 
observed in supplemented patients. Moreover, 
previous studies reported the efficacy of cur-
cumin-based supplementation in alleviating uri-
nary signs and symptoms of benign prostatic 
hyperplasia, including urgency, infections and 
retention20-22. Although curcumin is also func-
tional against inflammation, rheumatisms, and 
joint pain23-25, it has a low bioavailability; there-
fore, Oncotris™ includes Curcuma Enterosoma®, 
a patented technology that increases the absorp-
tion of substances that are scarcely bioavailable. 
This new oral delivery system has been projected 
aiming to improve BC (Berberina Chloride) ab-
sorption along enteric tract. The main concept 
surrounding this new technological system is 
the evidence described in many papers about the 
ability of Chitosan (CH) to interact with both 
enteric TJ (Tight Junctions)26,27 and PgP (P-gP 
protein)28,29. These phenomena are thought to be 
directly connected to the capability of CH and 
particularly cationized and quaternized chem-
ical derivatives of CH, to improve absorption 
of poorly absorbable molecules. Particularly, the 
acidic molecule selected to project this technol-
ogy is N-Acetylcysteine (NAC) that is a sul-
phureted N-Acetylated aminoacid very notorious 
as mucolytic agent. The tablet nucleus is coated 
with a gastro-resistant film to avoid premature 
cationization of CH occurring in the stomach 
by the side of gastric chloride acid that would 
compromise the enteric absorption enhancing 
effect. In the present study, curcumin-based sup-
plementation was also related to improvement in 
blood cell count, particularly white blood cells 
(4.8±0.5 vs. 4.3±0.8, expressed as 103/mm3), as al-
ready observed in previous in vitro investigations 
where curcumin showed radioprotective effects 
on human peripheral blood lymphocytes30. In our 
work, the Oncotris™ multi-component formula-
tion seemed to act also as anti-oxidant, reducing 
the level of free radical in genitourinary cancer 
patients (344±28 vs. 427±33 U-CARR). Besides 
curcumin, also astaxanthin and cordyceps have 
been recognized as active agents associated with 
oxidative stress protection31,32. Astaxanthin is 
a xanthophyll carotenoid found in microalgae, 
yeast and seafood that was approved as dietary 
supplement in 1999 by the Food and Drug Ad-
ministration33. Cordyceps are specific macrofun-
gi distributed worldwide, particularly in tropical 
forests and humid temperate, whose main chem-
ical constituents are cordycepin, an adenosine 
analogue, and polysaccharides34. Recently, some 
very preliminary studies are investigating the 
anti-proliferative and anti-metastatic action of 
some constituents of Oncotris35-43. However, these 
effects have null clinical value at present.
Conclusions 
Although with some limitations, such as het-
erogeneity of the study population and limited 
sample size, this work showed that a nutritional 
approach based on naturally-derived ingredients 
could support the body to overcome the treat-
ment-related side effects in the supportive man-
agement of genitourinary cancer.
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